Source comparison
Comparison Table: Sermorelin Dosing Protocols Across Clinical Contexts
200–300mcg nightly Age-related GH decline, mild insufficiency 140–180ng/mL 40–80ng/mL at 4 weeks Appropriate starting dose for most adults over 40 with preserved pituitary function. Test IGF-1 at week 4 before escalating 300–400mcg nightly Moderate GH insuffic
This comparison does not assign a generated winner or score.
- 200–300mcg nightly
- Age-related GH decline, mild insufficiency
- 140–180ng/mL
- 40–80ng/mL at 4 weeks
- Appropriate starting dose for most adults over 40 with preserved pituitary function. Test IGF-1 at week 4 before escalating
- 300–400mcg nightly
- Moderate GH insufficiency, body composition goals
- 100–140ng/mL
- 60–100ng/mL at 4 weeks
- Standard dose range for patients seeking measurable body composition changes. Requires IGF-1 monitoring every 4–6 weeks during titration
- 400–500mcg nightly
- Severe insufficiency, athletic recovery protocols
- 80–100ng/mL
- 80–120ng/mL at 4 weeks
- Upper end of clinical dosing. Monitor for side effects (water retention, joint pain) and retest IGF-1 every 4 weeks to avoid supraphysiological levels
- 500–1,000mcg nightly
- Research protocols, experimental dosing
- Variable
- Not recommended outside supervised research settings. Risk of excessive IGF-1 elevation, insulin resistance, and edema outweighs marginal benefit